NCT02781584 - Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

June 13, 2016

Primary Completion Date

December 17, 2020

Study Completion Date

December 17, 2020

Conditions

Nonalcoholic Steatohepatitis (NASH)Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

SEL

Administered orally once daily

DRUG

FIR

Administered orally once daily

DRUG

CILO

Administered orally once daily

DRUG

FENO

Administered orally once daily

DRUG

VAS

Administered orally two times daily

Trial Locations (13)

1010

Auckland Clinical Studies Ltd, Auckland

34211

Florida Research Institute, Lakewood Rch

37211

Quality Medical Research, Nashville

38138

Gastro One, Germantown

71220

Delta Research Partners, LLC, Bastrop

78215

American Research Corporation at the Texas Liver Institute, San Antonio

78229

Pinnacle Clinical Research, PLLC, San Antonio

78233

Pinnacle Clinical Research, PLLC, Live Oak

85224

Arizona Liver Health, Chandler

90036

Ruane Clinical Research Group Inc., Los Angeles

90048

Cedars-Sinai Medical Center, Los Angeles

92093

Altman Clinical and Translational Research Clinic, La Jolla

94305

Stanford Hospital and Clinics (SHC), Stanford